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Dietary long-chain n-3 PUFA (n-3 LCPUFA) are thought to have immune-modulating effects, but the specific effects and mechanisms are not fully
elucidated. The aim of this study was to determine whether dietary n-3 LCPUFA could affect ex vivo oxidative burst in healthy young men. The study
had a randomised 2 £ 2-factorial design in which subjects were randomly assigned to 8-week supplementation with capsules containing fish oil
(about 2·9 g n-3 LCPUFA/d) or olive oil (control). Subjects were also randomly assigned to household use of oils and fat spreads with a high or a
low 18 : 2n-6 content. At baseline and at the end of the intervention, the fatty acid composition of peripheral blood mononuclear cells (PBMC)
was analysed by GLC and oxidative burst was studied in whole blood stimulated with zymosan using luminol-enhanced chemiluminescence. The
PBMC content of n-3 LCPUFA was markedly increased by the fish oil-supplementation (P,0·001, compared to the olive oil groups). No effect
of the intervention was observed on neutrophil count, but one measure of the zymosan-induced oxidative burst was higher in the fish oil groups
(P¼0·03) compared to the olive oil groups. The fat intervention did not in itself affect oxidative burst neither did it change the effect of the fish-
oil intervention. The measures of oxidative burst at the end of the intervention period were found to be associated with the DHA content of
PBMC (r 0·44, P¼0·016), suggesting a dose–response relationship. These results indicate that n-3 LCPUFA may have immuno-stimulating effects.
Respiratory burst: Dietary supplementation: Inflammation: Human intervention study
Dietary long-chain ($C20) n-3 PUFA (n-3 LCPUFA) are
generally considered to be immuno-suppressive(1) and have
been shown to favourably affect a number of inflammatory
diseases including rheumatoid arthritis(2) and CVD(3,4). Neu-
trophils are central players in inflammatory diseases(5) as
they form part of the innate immune response, which acts
in the early host defence. Neutrophils kill microbes by releas-
ing proteolytic enzymes, superoxide and related reactive
oxygen species (ROS), a process referred to as oxidative
burst. ROS are toxic to the surrounding tissue, and the
damage provoked intensifies neutrophil activation, recruits
more neutrophils and thereby increases the inflammatory
response(6).
Feeding fish oil (FO), which contains n-3 LCPUFA, primar-
ily DHA and EPA, to laboratory animals has been shown
to decrease ex vivo neutrophil superoxide production measured
in isolated neutrophils(7,8). A number of ex vivo studies
have investigated the influence of FO supplements on oxi-
dative burst in healthy human volunteers, but the results are
conflicting. Some have found suppressive effects of FO(9–12)
whereas others have not(13–17).
The mechanisms by which n-3 LCPUFA exert their
immune-modulating actions are unknown. From a classical
point of view, the immuno-suppressive effect is thought to
operate through changes in eicosanoid production. It has, how-
ever, also been suggested that n-3 LCPUFA mediate their
effect by changes in gene expression or membrane struc-
ture(18,19). The NADPH oxidase, which is responsible for oxi-
dative burst, is a large membrane-associated protein complex
that assembles in lipid rafts(20). Lipid rafts are generated by
separation in the membrane bilayer of cholesterol and phos-
pholipids containing unsaturated fatty acids, especially
DHA(21). It is therefore plausible that the activity of the
NADPH oxidase could be affected by incorporation of DHA
into cellular membranes.
A common characteristic of many of the previous studies
investigating the effects of n-3 LCPUFA on oxidative burst
is that the oxidative burst assays were performed on isolated
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Abbreviations: ANCOVA, analysis of covariance; AUC, area under the curve; Des, desensitisation; FA%, fatty acid area percentage; FO, fish oil; n-3 LCPUFA,
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oil/Becel; T1
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P, time to half peak height; a40–60%, slope between 40 and 60% of peak height; D, changes in (endpoint value 2 baseline value).
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neutrophils(9,11–14,22). Recently, whole blood assays have
been developed(10,15,17), but in most cases the blood is kept
on ice prior to analysis (at 378C). Isolating, centrifuging,
cooling and heating neutrophils may change lipid struc-
ture(21,23). Especially in membranes with an increased content
of n-3 LCPUFA(24–26) as unsaturated fatty acids are structu-
rally more temperature-sensitive than SFA(21). This in turn
could affect neutrophil function and NADPH oxidase
activity(20,27).
In the present study we investigated whether 8 weeks of
dietary intervention affected ex vivo neutrophil oxidative
burst in healthy young men. In this 2 £ 2-fractional interven-
tion, FO supplements were combined with household use of
fats and oils with a high or low 18 : 2n-6 content. The effect
of the intervention on oxidative burst was measured ex vivo
using a whole blood chemiluminescence assay. The tempera-
ture was kept at 378C in order to mimic a normo-physiological
situation and avoid excessive manipulation of the neutrophils.
Methods
Subjects and study design
The present study was part of a larger intervention study
investigating the effects of FO-supplementation in combi-
nation with a high or low 18 : 2n-6 intake on tissue
PUFA-incorporation(28), CVD risk markers and cytokine
production in healthy young men. The study ran from Octo-
ber 2005 to February 2006. Healthy male subjects aged 18–
40 years were recruited by notes at universities throughout
Copenhagen. Subjects were invited to participate in the
study if they matched the following inclusion criteria:
BMI 18·5–27 kg/m2; non-smokers or infrequent smokers
(#5 cigarettes a week); daily consumption of butter, mar-
garine and/or oil, and home-made cooking $5 times per
week. Volunteers were excluded if they suffered from
chronic diseases or serious allergic symptoms, were taking
medication or dietary supplements, exercised more than 7 h
weekly or had donated blood within the last 2 months. Ethi-
cal permission for the study was obtained from the Ethical
Committee of the Municipalities of Frederiksberg and
Copenhagen (Journal No. KF 01 267804). The study was
registered in the clinical trial database of the US National
Institutes of Health (ClinicalTrials.gov, NCT00266292).
Informed written consent was obtained from all subjects
enrolled in the study.
The design of the study was as follows: a screening visit, a
2-week run-in period, a baseline visit, an 8-week intervention
period, an endpoint visit and a washout visit 8 weeks post-
intervention(28). The sub-study described in the present paper
ended after the subjects had completed the endpoint visit
and therefore does not contain any washout data. The follow-
ing sections describe only measurements relevant to this par-
ticular sub-study.
The study had a randomised-parallel 2 £ 2-factorial design
in which the subjects were randomly assigned to daily sup-
plementation with capsules containing either FO or olive oil
(OO, control) for 8 weeks. Subjects were also randomly
assigned to household use of oil and fat spreads with either
a high or a low 18 : 2n-6 content supplied by sunflower oil/
Becel (S/B) and rapeseed oil/Kaergaarden (R/K), respectively.
The randomisations were performed in two steps: first, notes
were drawn from one envelope for the capsule intervention
and second, within each capsule group notes were drawn for
the oil and fat spread intervention. Thus, the subjects were
randomly allocated in a double-blind fashion to one of four
intervention groups: (1) OO-capsules and S/B, (2) OO-cap-
sules and R/K, (3) FO-capsules and S/B or (4) FO-capsules
and R/K.
Capsules (in a defined surplus), fat spreads and oils speci-
fied by the randomisation were supplied to the subjects on
the day of their baseline visit. The subjects were instructed
to consume ten capsules per day (equal to 5ml/d) with FO
(Bio-Marin) or OO (both kindly provided by Pharma Nord,
Vejle, Denmark). Each FO-capsule contained 333mg n-3
PUFA (NEFA, approximately 166mg EPA and 119mg
DHA). The OO was given as TAG, but the capsules were
matched for fat content. The S/B groups were supplied
with sunflower oil (kindly provided by Aarhus United Den-
mark A/S, Aarhus, Denmark) and margarine (Becel 60,
kindly provided by Unilever Denmark A/S Foods, Brøndby,
Denmark) with a high content of 18 : 2n-6, whereas the R/K
groups were supplied with rapeseed oil (also a gift from
Aarhus United Denmark A/S) and a butter product contain-
ing two-thirds butter and one-third rapeseed oil (Kaergaar-
den Light, kindly provided by Arla Foods amba, Viby,
Denmark) with a low content of 18 : 2n-6. Both the margar-
ine and the butter products contained 60 g fat/100 g product.
Prior to the intervention period, all subjects were provided
with butter (Lurpak, also a gift from Arla Foods amba)
and OO (Oleificio R.M. s.p.a., Lucca, Italy) for a 2-week
run-in period. The purpose of this was to reset the fatty
acid composition of the tissue marker. There were no
restrictions concerning the amount of fat spreads or oil
ingested, but it was intended that the intake of fat and
energy remained constant during the study. The average
energy intake and the dietary composition were determined
by 4 d weighed dietary records: (1) prior to the run-in
period and (2) at the end of the 8-week intervention
period. The mean length of the intervention was 56 d
(range 50–65 d).
Seventy-five subjects were invited to a screening visit at
which height, weight, hip- and waist-circumference were
measured and the subjects were instructed in how to perform
the dietary records. Eight subjects dropped out during the
run-in period due to the workload of attendance and one sub-
ject was rejected at the baseline visit due to intense discom-
fort during blood sampling. This left us with sixty-six men
enrolled in the study, of which sixty-four completed the inter-
vention period. The reasons for drop-out were discomfort
swallowing the oil capsules (n 1) and the workload of attend-
ance (n 1). Furthermore, six subjects were left out from this
sub-study, four because no endpoint oxidative bursts were
measured and two because the baseline neutrophil count
failed (equipment error). Drop-outs and data collection fail-
ures were evenly distributed across the four intervention
groups. Data are reported only for those subjects with a com-
plete dataset (n 58). Furthermore, one analysis run stopped
(for an unknown reason), which resulted in a loss of three
subjects in all statistical tests of the area under the
curve (AUC) and desensitisation (Des) oxidative burst vari-
ables (n 55). The baseline characteristics of the subjects in
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each of the intervention groups are shown in Table 1.
Age, height, weight, BMI and waist/hip ratio did not differ
between the groups.
Fasting blood samples were collected at the baseline and
endpoint visits. The subjects were asked to follow standar-
dised fasting conditions before each visit. These were: no
food for 12 h or more (except from 0·5 litre water), lack of
strenuous physical activity for 36 h, no smoking for 1 week
and no medicine for 24 h. Moreover, the subjects were told
to eat the same meal the evening before all visits and to re-
schedule their visit if they were ill or had a cold. These criteria
were checked at every visit.
Experimental procedures
On the days of examination, body weight and waist/hip ratio
were determined. The subject filled out a questionnaire on
dietary habits, illnesses, use of medication and smoking.
Blood (80–110ml) was drawn from fasting males after
10min of rest and analysed for: oxidative burst, cell count,
Hb concentration and the fatty acid composition of peripheral
blood mononuclear cells (PBMC).
Compliance was assessed by counting returned capsules
and measuring tissue fatty acid composition of the PBMC.
The mean daily consumption of capsule oils was 4·5 (SD 0·5)
ml/d (range 3·0–5·5ml/d), equivalent to 89% compliance. No
difference in compliance was observed between the interven-
tion groups. The fatty acid composition in the total lipid frac-
tion from PBMC was determined as a biomarker of the
resulting changes in tissue composition.
Measuring fatty acid composition of the tissue
PBMC were isolated from blood sampled with Na-heparin and
fatty acid composition was determined by GLC as described
elsewhere(28). Fatty acids are given as area percentage
(FA%), comparable to g/100 g.
Neutrophil counts and Hb concentration
Neutrophil count was determined by leucocyte size diff-
erentiation carried out on a Sysmex KX-21 automated
haematology analyser (Sysmex Corporation, Kobe, Japan)
on venous blood collected in EDTA tubes using the appropri-
ate control. At the same time the Hb concentration was
measured. Intra- and interassay CV for Hb were 0·7%
(n 12) and 0·6% (n 25), respectively. Prior to the study
intra-individual variation in neutrophil count was determined
to 17·5% measured on three independent days in five
individuals.
Measurement of oxidative burst
Prior to the study all stock solutions were portioned and frozen
at 2208C. Zymosan A, a proteoglycan isolated from Sacchar-
omyces cerevisiae (Sigma-Aldrich, St Louis, MO, USA), was
suspended to 1mg/ml in Hank’s Balanced Salt Solution with
CaCl2 þ MgCl2 (Invitrogen, Carlsbad, CA, USA) and por-
tioned in aliquots of 300ml, and luminol (5-amino-2,3-dihy-
dro-1,4-phthalazinedione; Across Organics, NJ, USA) was
dissolved to 5mg/ml in dimethyl sulphoxide (Sigma-Aldrich)
and portioned in aliquots of 100ml.
Blood, sampled in Na-heparin tubes for assessment of oxi-
dative burst, was stored at 378C and oxidative burst was
determined within 2 h after sampling by chemiluminescence:
90ml whole blood diluted 1:9 in pre-warmed (378C) Hank’s
Balanced Salt Solution was loaded on ninety-six-well Lumi-
Nunce polystyrene plates (Nunc, Roskilde, Denmark), which
were preloaded with a 1:10 diluted stock solution of luminol
(10ml) with Hank’s Balanced Salt Solution in a final concen-
tration of 142mM/well. The diluted blood samples were
stimulated with 100ml pre-warmed (378C) zymosan at two
different final concentrations (5 and 0·5mg/ml). Chemilumi-
nescence (relative light units/s) was measured in a thermo-
stat-regulated (378C) ninety-six-well Orion II Microplate
Table 1. Baseline characteristics of the subjects in the four intervention groups (n 58)
Olive oil capsules Fish oil capsules
S/B (n 14) R/K (n 17) S/B (n 15) R/K (n 12) P †
Age (years) 0·61
Median 24 26 25 24
Percentiles‡ 22–27 22–28 22–27 22–25
Height (m) 0·17
Mean 1·80 1·84 1·83 1·85
SD 0·06 0·06 0·07 0·08
Weight (kg) 0·36
Median 74·4 79·4 72·9 75·2
Percentiles 69·6–79·0 73·1–84·3 65·8–81·3 69·3–82·0
BMI (kg/m2) 0·16
Mean 23·1 23·3 22·1 22·8
SD 1·9 1·9 1·6 2·2
Waist/hip ratio .0·99
Median 0·85 0·84 0·85 0·84
Percentiles 0·81–0·89 0·83–0·87 0·83–0·86 0·83–0·88
R/K, rapeseed oil/Kaergaarden; S/B, sunflower oil/Becel.
† Between-group comparisons were performed using one-way ANOVA and Kruskal–Wallis tests with significance established at
P,0·05. No significant differences were observed for any of the variables.
‡ Percentiles: 25th to 75th.
S. Bartelt et al.1232
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luminometer (Berthold Detection Systems, Pforzheim,
Germany). The microplate was read for 1 s/well with a
2min delay, a cycle repeated for a total of seventy-five
rounds. Unstimulated control samples (blanks) were analysed
in duplicate and stimulated samples in sextuplicate.
Five variables were used to define the kinetics of the mean
chemiluminescence response curve (Fig. 1): (1) time to half
peak height (T1
2
P), (2) peak height, (3) AUC, (4) slope
between 40 and 60% of peak height (a40–60%) and (5) Des.
All variables, except for AUC were calculated with Microsoft
Excel 2000 (Windows XP; Microsoft Corp., Redmond, WA,
USA) based on linear mathematical principles. AUC was
determined with GraphPad Prism version 4.00 (GraphPad
Prism, San Diego, CA, USA) based on integral calculation.
Prior to the study, the inter-day variation of the oxidative
burst variables was determined: blanks 2·4%, peak height
25·9%, AUC 29·6%, T1
2
P 3·8%, Des 48·5% and a40–60%
35·4% based on three independent days in five individuals.
Data were analysed with the Statistical Package for the
Social Sciences software version 13.0 (SPSS Inc., Chicago,
IL, USA). Data are only shown for the 5mg/ml zymosan-
stimulated samples. The results of the 0·5mg/ml zymosan-
stimulated samples were similar, but the responses were
smaller.
Statistical analyses
Data were checked for Gaussian distribution with Shapiro–
Wilks test and visual inspection of histograms. Gaussian-dis-
tributed data are presented as means with their standard
errors, whereas non-Gaussian-distributed data are presented
as medians with 25th–75th percentiles. Baseline comparison
between the four intervention groups were performed by
one-way ANOVA and Kruskal–Wallis tests. Analyses of
covariance (ANCOVA) were used for endpoint comparisons.
Non-Gaussian-distributed dependent variables (peak height,
AUC, Des, a40–60%) were log(10)-transformed before testing.
Statistical analysis was performed on the following: (1) the
effect of the interventions on the fatty acid composition of
PBMC, (2) the effect of the intervention on neutrophil count
and oxidative burst, and (3) the association between the
effect on oxidative burst and that on tissue fatty acid content.
The three statistical procedures were as follows:
(1) The ANCOVA for the endpoint comparisons of PBMC
fatty acid content (EPA, 22 : 5n-3, DHA and total n-3
PUFA) included fat type and capsule type as fixed factors
and were adjusted for baseline values. All models were
checked for interaction between the capsule and the oil/
fat spread interventions.
(2) All oxidative burst variables at endpoint were checked for
bivariate Spearman’s correlation with the following
covariates: neutrophil count (endpoint), changes in (D,
endpoint value 2 baseline value) neutrophil count, smok-
ing (yes/no) and D Hb concentration. Correlating par-
ameters (neutrophil count and D neutrophil count) were
tested as covariates in the ANCOVA endpoint compari-
son of the oxidative burst variables, which also included
fat type and capsule type as fixed factors (including check
for fat £ capsule interaction) and adjustment for baseline
values. Covariates were successively removed, but those
affecting the outcome (P,0·05) were kept in the model
(D neutrophil count).
(3) The dose–response relationship analysis of the oxidative
burst variables were performed using multiple linear
regression analysis including the following covariates:
endpoint PBMC DHA content, baseline values and the
covariates included in the oxidative burst variable
ANCOVA.
Wilcoxon test and paired-sample t test were used to check
for within-group changes during the intervention of non-Gaus-
sian-distributed and Gaussian-distributed data, respectively.
Associations between the estimated FO-consumption (from
the count of returned capsules (ml/d)) and D PBMC content
of total n-3 PUFA, DHA, 22 : 5n-3 and EPA was analysed
using Pearson correlation analysis. Significance was estab-
lished at P,0·05.
Results
The subjects had a mean energy intake of 12 531 (SD 2742) kJ/d
(range 6709–18 942 kJ/d), of which fat constituted 32·4 (SD 5·4)
% (range 20·0–43·0%) of energy. No between-group differ-
ences in energy consumption or macronutrient distribution
were observed at baseline or during the intervention(28). All sub-
jects maintained a constant weight during the study.
Fatty acid composition of mononuclear cells
The effect of the interventions on PBMC fatty acid compo-
sition has been published recently(28). In short, no differences
were observed in the PBMC content of total n-3 PUFA, DHA,
22 : 5n-3 or EPA between the treatment groups at baseline,
after 2 weeks of run-in where oil and fat spreads were standar-
dised. Endpoint comparison showed that 8 weeks of FO-sup-
plementation increased total n-3 PUFA, DHA, 22 : 5n-3 and
Fig. 1. Illustration of the luminol-enhanced chemiluminescence-detected oxi-
dative burst response in whole blood as a function of time, based on a ran-
domly selected participant. X, Non-stimulated mean response curve; W,
mean zymosan (Saccharomyces cerevisiae)-induced (5 mg/ml) response
curve. The response kinetics of the oxidative burst was expressed by five
selected variables: peak height (peak); area under the curve (AUC, ); time
to half peak (T12P); desensitisation (Des) and the slope between 40 and 60 %
of peak height (a40–60 %). RLU, relative light units.
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EPA; all of which were significantly higher (P,0·001, for all)
in the FO groups. The effects were supported by paired-
sample t-tests (P,0·001 for all fatty acid categories in both
FO groups). The best FO compliance marker was EPA,
which increased in the FO groups from 0·52 (SE 0·02) to
2·73 (SE 0·13) FA% in the PBMC compared to no changes
(0·44 (SE 0·02) to 0·39 (SE 0·02) FA%) in the OO groups.
The estimated FO-capsule consumption (count of returned
FO-capsules (ml/d)) correlated with endpoint PBMC EPA
content (r 0·51, P¼0·006), total n-3 PUFA content (r 0·48,
P¼0·011) and the DHA content (r 0·38, P¼0·049).
Neutrophils
The neutrophil counts at baseline did not differ between
the four intervention groups. The median count was
2·4 £ 109 cells/l (25th–75th percentiles 2·0–3·2 £ 109 cells/l),
ranging from 1·2 to 4·3 £ 109 cells/l. The interventions had
no effect on the cell counts. In general, the neutrophil count
of each subject was relatively constant (mean change of
0·66 (SD 0·88) £ 109 cells/l), but in five of the subjects the
cell count varied greatly ($1·8 £ 109 cells/l) between the
baseline and endpoint visit.
Oxidative burst
There were no differences between the four groups for any of
the oxidative burst variables at baseline. Four of the five oxi-
dative burst variables (with the exception of T1
2
P) correlated
with one another at baseline (0·89 , r , 0·99, P,0·001) and
after 8 weeks of intervention (0·35 , r , 0·52, P#0·007).
Bivariate correlations were observed between four of the five
oxidative burst endpoint variables (with the exception of T1
2
P,
P¼0·23) and endpoint neutrophil count (0·35 , r , 0·52,
P#0·007). The oxidative burst endpoint variables were
checked for correlation with confounders, such as Hb concen-
tration (possible quenching of emitted light) and if the
subject smoked (yes/no). No relations were observed, except
for a correlation between D Hb concentration and T1
2
P (r 0·29,
P¼0·03).
Eight weeks of capsule intervention were found to have a
significant effect on one of the five oxidative burst variables,
Des (P¼0·03; Table 2). No effects of the fat intervention or
of the capsules £ fat interaction term were observed (data
not shown). Two outliers were observed in the ANCOVA
model for peak height, AUC and Des (Fig. 2). After exclusion
of these two subjects, Des (P¼0·01), peak height (P¼0·02)
and AUC (P¼0·05) were significantly increased in the
FO-supplemented groups.
Dose–response relationship
Endpoint comparison of the oxidative burst variables correlated
significantlywith theDHAcontent in the PBMCat the end of the
intervention (r 0·44,P¼0·016 forDes andAUCshown in Fig. 3).
As for the capsule effect on oxidative burst, the two subjects
were also outliers in the dose–response relationship regression
models (for peak height, AUC and Des). Exclusion of the
two subjects in the analyses decreased the P value for the
dose–response relationships (Des (P¼0·010), peak height
(P¼0·047) and AUC (P¼0·02)). Similarly, a significant
dose–response relationship was observed for EPA (Des
(P¼0·029) and peak height (P¼0·047)), but to a lesser extent
than the one observed for DHA.
Discussion
The present results indicate that FO may increase oxidative
burst after 8 weeks of intervention, as one of five variables
was significantly increased in relation to the control sup-
plement. This was supported by outlier analysis and a dose–
response relationship between the oxidative burst and the
DHA content of immune cells (here PBMC). The effect was
most evident for the oxidative burst variables: peak height,
AUC and Des, but the oxidative burst variables were highly
inter-correlated. The present result is in agreement with a
recent study that found enhanced oxidative burst in healthy
young men after 8 weeks of FO-supplementation(29). How-
ever, both these studies contradict the results from previous
similar studies that have found either no effects(10,13–17) or a
reduction in the response(11,12). The two early studies that
observed a reduction in oxidative burst(11,12) were small (n 6
and n 22), had no control group, and gave little information
on inclusion and exclusion criteria and participant character-
istics (e.g. the mean age). In general, the more recent and
larger studies(10,13–17) have all reported no effect of n-3
LCPUFA-supplementation on oxidative burst in healthy
young men. All of these, except one(13), were randomised, pla-
cebo-controlled and double-blinded like the present study. The
FO-dose used in the present study (about 2·9 g n-3 LCPUFA/d)
was within the range provided in the previous studies(10–12,14).
We had only minor drop-outs and compliance was good as
judged from both capsule count and PBMC fatty acid analysis.
In agreement with results from a previous study(17), no effect
was observed on neutrophil counts. Most of the subjects had
very small changes in neutrophil count (comparable to the
intra-individual variation measured in our pre-study), but a
few varied more. Therefore, all analyses were adjusted for
the changes in neutrophil count.
A study by Rees et al.(10) suggested that the effect of FO-
supplementation may be age-related, since they found an
immuno-suppressive effect on oxidative burst in a group of
older subjects (aged 55–73 years), whereas no effect
was observed in a group of younger subjects (aged 18–52
years). However, another study found no effect of FO-sup-
plementation on oxidative burst in subjects aged 55–74
years(17). The most striking difference between these two
studies was the type of oils that they used. Thies et al.(17)
used five different oils including a pure DHA oil (700mg/d)
and a FO that supplied 720mg EPA/d and 280mg DHA/d,
whereas Rees et al.(10) used a pure EPA oil in four different
doses. Thus, it might be of interest to investigate possible
differences in the effects of EPA, DHA or a combination of
the two on oxidative burst in elderly subjects. The opposing
effects on the immune response in older versus young men
might be related to health status. It has been shown that FO
lowers cardiovascular risk markers, such as blood pressure(30)
and heart rate(31), primarily in high-risk subjects, e.g. elderly
or those with high baseline values. Whether the immuno-
stimulating effect of FO in the present study has any long-
term health effects is up for further investigation. Increased
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Table 2. Oxidative burst variables at baseline and endpoint in the four intervention groups (n 58)
Olive oil Fish oil
S/B (n 14) R/K (n 17) S/B (n 15) R/K (n 12)
Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint Fats P Capsules P
Blank (RLU/s)
Mean 32 34 34 34 32 35 33 33 0·53 0·98
SD 0·8 0·6 0·6 0·6 0·8 0·9 0·6 0·7
Peak (RLU/s)
Median 1531 1104* 1961 1219 1500 1155 1345 1471 0·33 0·09
Percentiles† 1417–2382 857–2005 1003–2637 885–2802 768–2194 728–2059 953–2198 1101–1640
AUC‡
Median 147 285 96 875* 140 861 106 327 118 235 100 013 120 713 124 240 0·14 0·19
Percentiles 99 295–199 145 72 228–13 0415 80 352–223 426 81 515–268 804 70 669–186 110 65 812–162 256 85 314–207 650 100 827–146 135
T12P (min)
Mean 52·48 52·14 51·67 51·84 52·22 52·43 52·61 52·11 1·00 0·84
SD 0·52 0·53 0·72 0·54 0·62 0·91 0·71 0·36
Des (RLU/s)‡
Median 697 446* 654 493 447 538 438 541 0·12 0·03§
Percentiles 279–1026 193–637 310–1000 284–912 205–923 277–918 302–493 363–809
a40–60 (RLU/s per min)
Median 70·9 49·8* 95·4 62·0 60·1 57·4 51·7 61·5 0·10 0·14
Percentiles 56·0–123·0 27·6–89·3 34·0–132·4 35·9–136·0 27·2–114·3 25·0–103·5 36·2–100·6 48·0–81·8
AUC, area under the curve; blank, non-stimulated control samples; Des, desensitisation; peak, peak height; RLU, relative light units; R/K, rapeseed oil/Kaergaarden; S/B, sunflower oil/Becel; T12P, time to half peak; a40–60, slope
between 40 and 60 % of peak height.
*Values were significantly different from those of the baseline (paired-sample t-test or Wilcoxon test): peak, P¼0·016; AUC, P¼0·016; Des, P¼0·026; a40–60, P¼0·013.
† Percentiles: 25th to 75th.
‡ Analysis stop (unknown reason), values for three subjects were lost leaving the groups with n 14, 14, 15 and 12 subjects, respectively for the AUC and Des analyses (n 55).
§ Endpoint between-group comparisons were performed using analysis of covariance with fats and capsules as fixed factors, adjusting for baseline values and changes in neutrophil count (endpoint 2 baseline).
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oxidative burst may have beneficial anti-bactericidal effects as
shown in mice(32).
The inconsistent results, concerning the effect of n-3
LCPUFA on oxidative burst, may to some extent be due to
the method of assessment. The more recent studies have
used fluorescence-activated cell-sorting analyses for detection
of ROS in isolated neutrophils(29) or whole blood(10,15,17). The
earlier studies have used isolated neutrophils assayed by either
luminol-enhanced chemiluminescence(11,12,16) or cytochrome
c reduction(12–14). The isolation procedure has a mechanical
impact on the neutrophils and may change the structure and
function of the cells. All the methods rely on chemical trap-
ping of ROS, which due to the extreme reactivity of superox-
ide is rapidly converted to other ROS. Some ROS are able to
cross membranes, which makes it difficult to distinguish
between intracellularly and extracellularly produced ROS.
Luminol-enhanced chemiluminiscence is thought to measure
intracellular as well as extracellular ROS, whereas the fluor-
escence-activated cell-sorting analyses only detect the intra-
cellular ROS. More methods could be used in parallel in
order to enhance the validity of the results. To our knowledge,
this is the first study to use chemiluminescence to study the
effect of FO-supplementation on oxidative burst ex vivo in
whole blood. The advantage of the whole blood assay is that
the neutrophils are kept in their physiological environment.
We handled the blood for the assay as gently as possible
throughout the entire procedure and performed the assay at
378C. Furthermore, we used a sub-maximal stimulus (a zymo-
san–neutrophil ratio of 2·4) to induce an oxidative burst,
which may also be more physiologically relevant than the
use of surplus stimulus to ensure a 100% cell activation as
is done in most other studies(10,15,17).
We used OO as capsule control because it has a low content
of PUFA, especially n-3 PUFA, and because 18 : 1n-9 was
regarded as a neutral fatty acid. The use of an OO control
in studies of immune function has been questioned since
some studies have reported effects on immune function after
OO-supplementation(33,34). The observed effect of the capsule
intervention appears to be due to a reduction in the oxidative
burst, especially when assessed as Des, in the OO groups
rather than an increase in the FO groups. However, due to
the observed correlation between the oxidative burst effect
and the PBMC content of DHA we find it unlikely that the
effect is driven by the OO. The observed dose–response cor-
relation was not so strong (r 0·27, P¼0·04), but since this was
interfered with by inter-day variation (biological as well as
methodological, which for AUC amounted to 29·6%) it may
in reality represent a stronger true biological dose–response
relationship. A dietary PUFA-induced increased membrane
DHA content in Jurkat T-cells was shown to be paralleled
by a decrease in MUFA(35). No inverse association between
DHA and MUFA was observed in the present study (data
not shown) and it is therefore not likely that the correlation
between DHA and oxidative burst could reflect an indirect
association with 18 : 1n-9.
In general, changes in the fatty acid composition of all
immune cells are related to the dose(10,15) and the length of
Fig. 2. The effect of the capsule intervention on desensitisation (Des). (A), Des values for each participant at the end of the intervention are plotted in each of the
two capsule groups (OO, olive oil (control); FO, fish oil). Two subjects had outlying Des values. These are given above a break on the y-axis (– –). (B), Des values
were adjusted for baseline value and D neutrophil count. * Significant difference between the oxidative burst in the capsule groups by analysis of covariance
(P¼0·03). —, Median; RLU, relative light units.
Fig. 3. The correlation between DHA in the peripheral blood mononuclear
cells (PBMC) and the oxidative burst expressed as area under the curve
(AUC) after 8 weeks of intervention with capsules with fish oil ( ) or olive oil
(control, ). AUC and PBMC DHA were adjusted for baseline value of oxi-
dative burst and changes in neutrophil count during the intervention. —,
Regression curve with 95 % CI (. . .) based on n 55 (r 0·27, P¼0·04); %FA,
fatty acid area percentage.
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intervention(26). The DHA content of the PBMC was signifi-
cantly increased after 8 weeks of FO-supplementation as
expected(36) and parallel changes have most likely also occurred
in the neutrophils, as observed by Gibney & Hunter(26). The
active NADPH oxidase-complex has been shown to be located
in membrane domains, which are rich in saturated acyl groups,
the so-called lipid rafts(20). Lipid rafts are formed by segregation
of cholesterol and sphingolipids from DHA-containing phos-
pholipids(21). It was therefore our baseline assumption, although
we did not test this, that increased incorporation of DHA could
lower the lipid raft area andhave functional consequences equiv-
alent to that of cholesterol extraction. Cholesterol depletion of
HL-60 cells (a neutrophil-like cell line) has been shown to
result in a dramatic reduction in NADPH oxidase activity(20).
Similar effects were observed in a number of other raft-associ-
ated proteins in Jurkat T cells and isolated human neutro-
phils(35,37). Furthermore, cholesterol depletion has been linked
to a decrease in raft-associated protein trafficking(37), and thus
may affect the assembly of the NADPH oxidase complex. An
ex vivo study of PUFA-supplemented Jurkat T cells showed a
selective modification of unsaturation in the cytoplasmic layer
of the detergent-resistant membrane domains (lipid rafts) and
an associated inhibition of T cell signal transduction(35). We
did not determine whether the increased intake of n-3
LCPUFA had any effect on the microdomain structure and, to
our knowledge, this has not been done in any previous studies.
The observed effect of the capsule intervention corresponds
poorly with this baseline assumption. The effect of the FO sup-
plement on neutrophil function may therefore be explained by
other mechanisms. Several effects of n-3 LCPUFA in other
cell types (monocyte, B lymphocyte and T lymphocyte) are
thought to be exerted via alterations in gene expression and tran-
scription factors such as PPAR(38,39). Gorja˜o et al.(29) showed
modification of seventy-seven genes in human lymphocytes
after FO-supplementation, most of which were related to signal-
ling pathways. According to the classical hypotheses, the
immuno-suppressive effect of n-3 LCPUFA is thought to be
caused by changes in eicosanoid production (e.g. modulation
of the LTB4 levels
(40)). However, blocking of eicosanoid pro-
duction by a cyclo-oxygenase inhibitor (indomethacin) has
been shown not to affect oxidative burst(22).
In conclusion, the present study suggests an immuno-stimu-
lating effect on oxidative burst after 8 weeks of FO-sup-
plementation in healthy young men. The effect seems to be
related to the cellular DHA content, but the mechanism
remains to be determined.
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